Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
24 June 2022 - 06:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR
15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF JUNE 2022
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation
of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F
☒
Form 40‑F
☐
Indicate by check mark if the registrant is submitting the Form 6‑K
in paper as permitted by Regulation S‑T Rule 101(b)(1):
☐
Indicate by check mark if the registrant is submitting the Form 6‑K
in paper as permitted by Regulation S‑T Rule 101(b)(7):
☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On June 23, 2022, BioNTech SE (the “Company”) today announced that
that the European Medicines Agency (EMA) has granted Priority
Medicines (PRIME) designation to BioNTech’s fully owned product
candidate BNT211 for the third- or later-line treatment of
testicular germ cell tumors. The press release is attached hereto
as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
BioNTech SE |
|
|
|
|
|
|
|
By: |
/s/ Dr. Sierk Poetting |
|
|
Name: Dr. Sierk Poetting |
|
|
Title: Chief Operating Officer |
Date: June 23, 2022
EXHIBIT INDEX
|
|
|
|
|
|
|
|
|
Exhibit |
Description of Exhibit |
|
|
|
99.1 |
|
|
|
|
|
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Jul 2022 to Aug 2022
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Aug 2021 to Aug 2022
